Based on Siewert classification: controversy progress of the integration of type<b> Ⅱ </b>of adenocarcinoma of esophagogastric junction_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

CHENG Jie ^1,2 ,  HUANG Bo ²

1. Shanxi Medical University, Taiyuan 030001, P. R. China;
2. Department of Gastrointestinal Surgery, People’s Hospital Affiliated to Shanxi Medical University,Taiyuan 030012, P. R. China;

Corresponding author：

HUANG Bo, Email: huangbo1408@sina.com

Keywords：

adenocarcinoma of esophagogastric junction; stage; surgical treatment; laparoscopic treatment; adjuvant therapy

DOI：

10.7507/1007-9424.202011053

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To review and summarize the research progress of adenocarcinoma of esophagogastric junction (AEG) in staging, surgical treatment, endoscopic treatment and adjuvant therapy in recent years, so as to provide reference and help for the follow-up research and treatment of this disease.Method Literature review was used to review the literatures on AEG treatment in various databases.Results The incidence of AEG had increased rapidly in recent years, with high malignancy and poor prognosis. Siewert typing had allowed researchers to gain insight into the disease, and treatments were increasingly diversified. At present, the main treatment was still radical surgery. Because AEG was adjacent to the esophagus and stomach, there were many controversies about its staging, surgical approach, resection range, digestive tract reconstruction, adjuvant treatment and so on, especially Siewert type Ⅱ.Conclusions The surgical approach, resection range, and laparoscopic surgery of Siewert typeⅡcan choose according to esophageal involvement distance judgment, pathological staging is uncertain, still need several studies to reach a consensus. With the application of laparoscopy and adjuvant therapy, how to select individualized treatment options that require multidisciplinary collaboration for further study.

Citation： CHENG Jie, HUANG Bo. Based on Siewert classification: controversy progress of the integration of type Ⅱ of adenocarcinoma of esophagogastric junction. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(9): 1254-1260. doi: 10.7507/1007-9424.202011053 Copy

1.	刘凯, 张维汉, 陈心足. 食管胃结合部腺癌的定义、分型和分期: 争议中的进展. 中国普外基础与临床杂志, 2019, 26(9): 1040-1045.
2.	国际食管疾病学会中国分会(CSDE)食管胃结合部疾病跨界联盟, 中国医师协会内镜医师分会腹腔镜外科专业委员会, 中国医师协会外科医师分会上消化道外科医师专业委员会中华医学会, 等. 食管胃结合部腺癌外科治疗中国专家共识(2018年版). 中华胃肠外科杂志, 2018, 21(9): 961-975.
3.	日本胃癌学会. 胃癌取扱い規約. 15版. 東京: 金原出版株式会社, 2017: 8.
4.	Japan Esophageal Society. Japanese Classification of Esophageal Cancer, 11^th Edition: part Ⅰ. Esophagus, 2017, 14(1): 1-36.
5.	季加孚, 季科. 食管胃结合部腺癌外科治疗进展. 中国普外基础与临床杂志, 2019, 26(9): 1021-1024.
6.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
7.	Liu K, Yang K, Zhang W, et al. Changes of esophagogastric junctional adenocarcinoma and gastroesophageal reflux disease among surgical patients during 1988-2012: a single-institution, high-volume experience in China. Ann Surg, 2016, 263(1): 88-95.
8.	杨宏, 武爱文, 季加孚, 等. 食管胃结合部腺癌471例Siewert分型临床研究. 中国实用外科杂志, 2012, 32(4): 310-315.
9.	Zhang Y, Liu D, Zeng D, et al. Lymph node ratio is an independent prognostic factor for patients with Siewert type Ⅱ adenocarcinoma of esophagogastric junction: results from a 10-year follow-up study. J Gastrointest Cancer, 2020 Sep 21. Online ahead of print.
10.	Sugita S, Kinoshita T, Kuwata T, et al. Long-term oncological outcomes of laparoscopic versus open transhiatal resection for patients with Siewert type Ⅱ adenocarcinoma of the esophagogastric junction. Surg Endosc, 2021, 35(1): 340-348.
11.	李浩淼, 孙海波, 郑燕, 等. AJCC/UICC第八版食管及食管胃交界部癌TNM分期解读及中文版主要内容. 中国胸心血管外科临床杂志, 2017, 24(2): 87-92.
12.	郗洪庆, 张珂诚, 卫勃, 等. 胃癌TNM分期第八版更新在临床诊断治疗中的意义和思考. 中华胃肠外科杂志, 2017, 20(2): 166-170.
13.	Hasegawa S, Yoshikawa T, Aoyama T, et al. Esophagus or stomach? The seventh TNM classification for Siewert type Ⅱ/Ⅲ junctional adenocarcinoma. Ann Surg Oncol, 2013, 20(3): 773-779.
14.	陕飞, 李子禹, 张连海, 等. 国际抗癌联盟及美国肿瘤联合会胃癌TNM分期系统(第8版)简介及解读. 中国实用外科杂志, 2017, 37(1): 15-17.
15.	Liu K, Feng F, Chen XZ, et al. Comparison between gastric and esophageal classification system among adenocarcinomas of esophagogastric junction according to AJCC 8th edition: a retrospective observational study from two high-volume institutions in China. Gastric Cancer, 2019, 22(3): 506-517.
16.	Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, et al. Integrated genomic characterization of oesophageal carcinoma. Nature, 2017, 541(7636): 169-175.
17.	Barra WF, Moreira FC, Pereira Cruz AM, et al. GEJ cancers: gastric or esophageal tumors? searching for the answer according to molecular identity. Oncotarget, 2017, 8(61): 104286-104294.
18.	Suh YS, Na D, Lee JS, et al. Comprehensive molecular characterization of adenocarcinoma of the gastroesophageal junction between esophageal and gastric adenocarcinomas. Ann Surg, 2020 Oct 19. Online ahead of print.
19.	Koyanagi K, Kato F, Kanamori J, et al. Clinical significance of esophageal invasion length for the prediction of mediastinal lymph node metastasis in Siewert type Ⅱ adenocarcinoma: A retrospective single-institution study. Ann Gastroenterol Surg, 2018, 2(3): 187-196.
20.	高军, 李富良, 何旭. Ⅱ/Ⅲ型胃食管结合部腺癌淋巴结转移的影响因素及其对预后的影响. 中国普外基础与临床杂志, 2018, 25(11): 1327-1331.
21.	Mitchell KG, Ikoma N, Nelson DB, et al. Mediastinal nodal involvement after neoadjuvant chemoradiation for Siewert Ⅱ/Ⅲ adenocarcinoma. Ann Thorac Surg, 2019, 108(3): 845-851.
22.	Kurokawa Y, Takeuchi H, Doki Y, et al. Mapping of lymph node metastasis from esophagogastric junction tumors: a prospective nationwide multicenter study. Ann Surg, 2019 Aug 8. Online ahead of print.
23.	中华医学会外科学分会腹腔镜与内镜外科学组. Siewert Ⅱ型食管胃结合部腺癌腔镜手术治疗中国专家共识(2019版). 中国实用外科杂志, 2019, 39(11): 1129-1135.
24.	郭伟. 食管胃结合部腺癌的淋巴结清扫范围. 中国现代普通外科进展, 2020, 23(10): 769-772.
25.	林密, 吕陈彬, 郑朝辉, 等. 脾门淋巴结清扫在肿瘤长径≥4 cm的Siewert Ⅱ型和Ⅲ型食管胃结合部腺癌中的应用价值. 中华消化外科杂志, 2016, 15(11): 1055-1061.
26.	Lin JX, Zheng CH, Huang CM. Comment on "Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma". Ann Surg, 2019, 269(5): e65.
27.	于振涛, 王海通. 食管胃结合部腺癌外科治疗现状. 中华消化外科杂志, 2019, 18(6): 513-517.
28.	Kurokawa Y, Sasako M, Sano T, et al. Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg, 2015, 102(4): 341-348.
29.	杨世界, 袁勇, 刘凯, 等. SiewertⅡ型食管胃结合部腺癌经胸与经腹入路手术的预后比较—胸外科与胃肠外科联合数据分析. 中华胃肠外科杂志, 2019, 22(2): 132-142.
30.	Wu H, Shang L, Du F, et al. Transhiatal versus transthoracic surgical approach for Siewert type Ⅱ adenocarcinoma of the esophagogastric junction: a meta-analysis. Expert Rev Gastroenterol Hepatol, 2020, 14(11): 1107-1117.
31.	胡文庆, 崔鹏, 张晋杰, 等. 经腹食管裂孔入路下纵隔淋巴结清扫在食管胃结合部腺癌手术中的应用. 中国普通外科杂志, 2019, 28(10): 1192-1196.
32.	Niclauss N, Jung MK, Chevallay M, et al. Minimal length of proximal resection margin in adenocarcinoma of the esophagogastric junction: a systematic review of the literature. Updates Surg, 2019, 71(3): 401-409.
33.	张维汉, 张东阳, 陈心足, 等. 胃上部腺癌全胃切除术与近端胃切除术安全性及有效性比较的Meta分析. 中华胃肠外科杂志, 2019, 22(5): 470-478.
34.	Takiguchi N, Takahashi M, Ikeda M, et al. Long-term quality-of-life comparison of total gastrectomy and proximal gastrectomy by postgastrectomy syndrome assessment scale (PGSAS-45): a nationwide multi-institutional study. Gastric Cancer, 2015, 18(2): 407-416.
35.	《SiewertⅡ型食管胃结合部腺癌腔镜手术治疗中国专家共识(2019版)》编写委员会. 近端胃切除消化道重建中国专家共识(2020版). 中华胃肠外科杂志, 2020, 23(2): 101-108.
36.	刘晓菊, 姚芮. 近端胃切除术后两种消化道重建方式的安全性及生活质量对比研究. 中华普外科手术学杂志(电子版), 2020, 14(3): 285-288.
37.	徐宁, 董剑宏, 张万红, 等. 近端胃切除背驮式间置空肠吻合两种重建方式治疗SiewertⅡ~Ⅲ型食管胃结合部腺癌的比较研究. 中华外科杂志, 2019, 57(2): 114-118.
38.	郑朝辉, 郑华龙, 陆俊. 基于Siewert分型食管胃结合部腺癌的治疗策略. 中华消化外科杂志, 2019, 18(6): 536-541.
39.	Huang CM, Lv CB, Lin JX, et al. Laparoscopic-assisted versus open total gastrectomy for Siewert type Ⅱ and Ⅲ esophagogastric junction carcinoma: a propensity score-matched case-control study. Surg Endosc, 2017, 31(9): 3495-3503.
40.	Liao C, Feng Q, Xie S, et al. Laparoscopic versus open gastrectomy for Siewert type Ⅱ/Ⅲ adenocarcinoma of the esophagogastric junction: a meta-analysis. Surg Endosc, 2021, 35(2): 860-871.
41.	Sun X, Wang G, Liu C, et al. Comparison of short-term outcomes following minimally invasive versus open Sweet esophagectomy for Siewert type Ⅱ adenocarcinoma of the esophagogastric junction. Thorac Cancer, 2020, 11(6): 1487-1494.
42.	宋舜尧, 韩璐, 袁庆忠, 等. 完全腹腔镜下经腹入路与经腹联合开胸手术入路治疗SiewertⅡ型食管胃结合部腺癌的对比研究. 中国普外基础与临床杂志, 2020, 27(10): 1259-1265.
43.	贾卓奇, 周维茹, 李硕, 等. SiewertⅠ型和Ⅱ型食管胃结合部癌不同手术方式的近期疗效分析. 中国胸心血管外科临床杂志, 2020, 27(4): 431-435.
44.	Liu F, Huang C, Xu Z, et al. Morbidity and mortality of laparoscopic vs open total gastrectomy for clinical stage Ⅰ gastric cancer: The CLASS02 multicenter randomized clinical trial. JAMA Oncol, 2020, 6(10): 1590-1597.
45.	Katai H, Mizusawa J, Katayama H, et al. Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage Ⅰ gastric cancer: Japan Clinical Oncology Group study JCOG1401. Gastric Cancer, 2019, 22(5): 999-1008.
46.	田艳涛, 马福海. MDT在食管胃结合部腺癌治疗中的作用. 中国普外基础与临床杂志, 2019, 26(9): 1035-1039.
47.	林佳锐, 庄业忠, 王伟峰, 等. 新辅助化疗治疗可切除局部晚期食管胃结合部腺癌的疗效分析. 中华消化外科杂志, 2018, 17(6): 619-625.
48.	刘培根, 颜璟, 吴艳军, 等. 术前新辅助化疗治疗可切除局部晚期Siewert Ⅱ、Ⅲ型食管胃结合部腺癌效果分析. 肿瘤研究与临床, 2020, 32(6): 394-399.
49.	Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet, 2019, 393(10184): 1948-1957.
50.	Liu F, Zhou R, Jiang F, et al. Proposal of a nomogram for predicting survival in patients with Siewert type Ⅱ adenocarcinoma of the esophagogastric junction after preoperative radiation. Ann Surg Oncol, 2019, 26(5): 1292-1300.
51.	孙黎, 邱红, 袁响林. 霜重鼓寒—2019ASCO后胃癌围手术期放疗再思考. 实用肿瘤杂志, 2019, 34(5): 396-401.
52.	de Steur WO, van Amelsfoort RM, Hartgrink HH, et al. Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial. Ann Oncol, 2021, 32(3): 360-367.
53.	Fitzgerald TL, Efird JT, Bellamy N, et al. Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5 058 patients. Cancer, 2017, 123(15): 2909-2917.
54.	Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol, 2015, 16(9): 1090-1098.
55.	Noordman BJ, Verdam MGE, Lagarde SM, et al. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial. Ann Oncol, 2018, 29(2): 445-451.
56.	Cheng Y, Wang J, Li J. Comparative analysis of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy with resectable adenocarcinoma of esophagogastric junction in Siewert’s type Ⅱand Ⅲ. Int J Radiat Oncol Biol Phys (IJROBP), 2019, 105(1S): E182-E183.

1. 刘凯, 张维汉, 陈心足. 食管胃结合部腺癌的定义、分型和分期: 争议中的进展. 中国普外基础与临床杂志, 2019, 26(9): 1040-1045.
2. 国际食管疾病学会中国分会(CSDE)食管胃结合部疾病跨界联盟, 中国医师协会内镜医师分会腹腔镜外科专业委员会, 中国医师协会外科医师分会上消化道外科医师专业委员会中华医学会, 等. 食管胃结合部腺癌外科治疗中国专家共识(2018年版). 中华胃肠外科杂志, 2018, 21(9): 961-975.
3. 日本胃癌学会. 胃癌取扱い規約. 15版. 東京: 金原出版株式会社, 2017: 8.
4. Japan Esophageal Society. Japanese Classification of Esophageal Cancer, 11^th Edition: part Ⅰ. Esophagus, 2017, 14(1): 1-36.
5. 季加孚, 季科. 食管胃结合部腺癌外科治疗进展. 中国普外基础与临床杂志, 2019, 26(9): 1021-1024.
6. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
7. Liu K, Yang K, Zhang W, et al. Changes of esophagogastric junctional adenocarcinoma and gastroesophageal reflux disease among surgical patients during 1988-2012: a single-institution, high-volume experience in China. Ann Surg, 2016, 263(1): 88-95.
8. 杨宏, 武爱文, 季加孚, 等. 食管胃结合部腺癌471例Siewert分型临床研究. 中国实用外科杂志, 2012, 32(4): 310-315.
9. Zhang Y, Liu D, Zeng D, et al. Lymph node ratio is an independent prognostic factor for patients with Siewert type Ⅱ adenocarcinoma of esophagogastric junction: results from a 10-year follow-up study. J Gastrointest Cancer, 2020 Sep 21. Online ahead of print.
10. Sugita S, Kinoshita T, Kuwata T, et al. Long-term oncological outcomes of laparoscopic versus open transhiatal resection for patients with Siewert type Ⅱ adenocarcinoma of the esophagogastric junction. Surg Endosc, 2021, 35(1): 340-348.
11. 李浩淼, 孙海波, 郑燕, 等. AJCC/UICC第八版食管及食管胃交界部癌TNM分期解读及中文版主要内容. 中国胸心血管外科临床杂志, 2017, 24(2): 87-92.
12. 郗洪庆, 张珂诚, 卫勃, 等. 胃癌TNM分期第八版更新在临床诊断治疗中的意义和思考. 中华胃肠外科杂志, 2017, 20(2): 166-170.
13. Hasegawa S, Yoshikawa T, Aoyama T, et al. Esophagus or stomach? The seventh TNM classification for Siewert type Ⅱ/Ⅲ junctional adenocarcinoma. Ann Surg Oncol, 2013, 20(3): 773-779.
14. 陕飞, 李子禹, 张连海, 等. 国际抗癌联盟及美国肿瘤联合会胃癌TNM分期系统(第8版)简介及解读. 中国实用外科杂志, 2017, 37(1): 15-17.
15. Liu K, Feng F, Chen XZ, et al. Comparison between gastric and esophageal classification system among adenocarcinomas of esophagogastric junction according to AJCC 8th edition: a retrospective observational study from two high-volume institutions in China. Gastric Cancer, 2019, 22(3): 506-517.
16. Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, et al. Integrated genomic characterization of oesophageal carcinoma. Nature, 2017, 541(7636): 169-175.
17. Barra WF, Moreira FC, Pereira Cruz AM, et al. GEJ cancers: gastric or esophageal tumors? searching for the answer according to molecular identity. Oncotarget, 2017, 8(61): 104286-104294.
18. Suh YS, Na D, Lee JS, et al. Comprehensive molecular characterization of adenocarcinoma of the gastroesophageal junction between esophageal and gastric adenocarcinomas. Ann Surg, 2020 Oct 19. Online ahead of print.
19. Koyanagi K, Kato F, Kanamori J, et al. Clinical significance of esophageal invasion length for the prediction of mediastinal lymph node metastasis in Siewert type Ⅱ adenocarcinoma: A retrospective single-institution study. Ann Gastroenterol Surg, 2018, 2(3): 187-196.
20. 高军, 李富良, 何旭. Ⅱ/Ⅲ型胃食管结合部腺癌淋巴结转移的影响因素及其对预后的影响. 中国普外基础与临床杂志, 2018, 25(11): 1327-1331.
21. Mitchell KG, Ikoma N, Nelson DB, et al. Mediastinal nodal involvement after neoadjuvant chemoradiation for Siewert Ⅱ/Ⅲ adenocarcinoma. Ann Thorac Surg, 2019, 108(3): 845-851.
22. Kurokawa Y, Takeuchi H, Doki Y, et al. Mapping of lymph node metastasis from esophagogastric junction tumors: a prospective nationwide multicenter study. Ann Surg, 2019 Aug 8. Online ahead of print.
23. 中华医学会外科学分会腹腔镜与内镜外科学组. Siewert Ⅱ型食管胃结合部腺癌腔镜手术治疗中国专家共识(2019版). 中国实用外科杂志, 2019, 39(11): 1129-1135.
24. 郭伟. 食管胃结合部腺癌的淋巴结清扫范围. 中国现代普通外科进展, 2020, 23(10): 769-772.
25. 林密, 吕陈彬, 郑朝辉, 等. 脾门淋巴结清扫在肿瘤长径≥4 cm的Siewert Ⅱ型和Ⅲ型食管胃结合部腺癌中的应用价值. 中华消化外科杂志, 2016, 15(11): 1055-1061.
26. Lin JX, Zheng CH, Huang CM. Comment on "Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma". Ann Surg, 2019, 269(5): e65.
27. 于振涛, 王海通. 食管胃结合部腺癌外科治疗现状. 中华消化外科杂志, 2019, 18(6): 513-517.
28. Kurokawa Y, Sasako M, Sano T, et al. Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg, 2015, 102(4): 341-348.
29. 杨世界, 袁勇, 刘凯, 等. SiewertⅡ型食管胃结合部腺癌经胸与经腹入路手术的预后比较—胸外科与胃肠外科联合数据分析. 中华胃肠外科杂志, 2019, 22(2): 132-142.
30. Wu H, Shang L, Du F, et al. Transhiatal versus transthoracic surgical approach for Siewert type Ⅱ adenocarcinoma of the esophagogastric junction: a meta-analysis. Expert Rev Gastroenterol Hepatol, 2020, 14(11): 1107-1117.
31. 胡文庆, 崔鹏, 张晋杰, 等. 经腹食管裂孔入路下纵隔淋巴结清扫在食管胃结合部腺癌手术中的应用. 中国普通外科杂志, 2019, 28(10): 1192-1196.
32. Niclauss N, Jung MK, Chevallay M, et al. Minimal length of proximal resection margin in adenocarcinoma of the esophagogastric junction: a systematic review of the literature. Updates Surg, 2019, 71(3): 401-409.
33. 张维汉, 张东阳, 陈心足, 等. 胃上部腺癌全胃切除术与近端胃切除术安全性及有效性比较的Meta分析. 中华胃肠外科杂志, 2019, 22(5): 470-478.
34. Takiguchi N, Takahashi M, Ikeda M, et al. Long-term quality-of-life comparison of total gastrectomy and proximal gastrectomy by postgastrectomy syndrome assessment scale (PGSAS-45): a nationwide multi-institutional study. Gastric Cancer, 2015, 18(2): 407-416.
35. 《SiewertⅡ型食管胃结合部腺癌腔镜手术治疗中国专家共识(2019版)》编写委员会. 近端胃切除消化道重建中国专家共识(2020版). 中华胃肠外科杂志, 2020, 23(2): 101-108.
36. 刘晓菊, 姚芮. 近端胃切除术后两种消化道重建方式的安全性及生活质量对比研究. 中华普外科手术学杂志(电子版), 2020, 14(3): 285-288.
37. 徐宁, 董剑宏, 张万红, 等. 近端胃切除背驮式间置空肠吻合两种重建方式治疗SiewertⅡ~Ⅲ型食管胃结合部腺癌的比较研究. 中华外科杂志, 2019, 57(2): 114-118.
38. 郑朝辉, 郑华龙, 陆俊. 基于Siewert分型食管胃结合部腺癌的治疗策略. 中华消化外科杂志, 2019, 18(6): 536-541.
39. Huang CM, Lv CB, Lin JX, et al. Laparoscopic-assisted versus open total gastrectomy for Siewert type Ⅱ and Ⅲ esophagogastric junction carcinoma: a propensity score-matched case-control study. Surg Endosc, 2017, 31(9): 3495-3503.
40. Liao C, Feng Q, Xie S, et al. Laparoscopic versus open gastrectomy for Siewert type Ⅱ/Ⅲ adenocarcinoma of the esophagogastric junction: a meta-analysis. Surg Endosc, 2021, 35(2): 860-871.
41. Sun X, Wang G, Liu C, et al. Comparison of short-term outcomes following minimally invasive versus open Sweet esophagectomy for Siewert type Ⅱ adenocarcinoma of the esophagogastric junction. Thorac Cancer, 2020, 11(6): 1487-1494.
42. 宋舜尧, 韩璐, 袁庆忠, 等. 完全腹腔镜下经腹入路与经腹联合开胸手术入路治疗SiewertⅡ型食管胃结合部腺癌的对比研究. 中国普外基础与临床杂志, 2020, 27(10): 1259-1265.
43. 贾卓奇, 周维茹, 李硕, 等. SiewertⅠ型和Ⅱ型食管胃结合部癌不同手术方式的近期疗效分析. 中国胸心血管外科临床杂志, 2020, 27(4): 431-435.
44. Liu F, Huang C, Xu Z, et al. Morbidity and mortality of laparoscopic vs open total gastrectomy for clinical stage Ⅰ gastric cancer: The CLASS02 multicenter randomized clinical trial. JAMA Oncol, 2020, 6(10): 1590-1597.
45. Katai H, Mizusawa J, Katayama H, et al. Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage Ⅰ gastric cancer: Japan Clinical Oncology Group study JCOG1401. Gastric Cancer, 2019, 22(5): 999-1008.
46. 田艳涛, 马福海. MDT在食管胃结合部腺癌治疗中的作用. 中国普外基础与临床杂志, 2019, 26(9): 1035-1039.
47. 林佳锐, 庄业忠, 王伟峰, 等. 新辅助化疗治疗可切除局部晚期食管胃结合部腺癌的疗效分析. 中华消化外科杂志, 2018, 17(6): 619-625.
48. 刘培根, 颜璟, 吴艳军, 等. 术前新辅助化疗治疗可切除局部晚期Siewert Ⅱ、Ⅲ型食管胃结合部腺癌效果分析. 肿瘤研究与临床, 2020, 32(6): 394-399.
49. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet, 2019, 393(10184): 1948-1957.
50. Liu F, Zhou R, Jiang F, et al. Proposal of a nomogram for predicting survival in patients with Siewert type Ⅱ adenocarcinoma of the esophagogastric junction after preoperative radiation. Ann Surg Oncol, 2019, 26(5): 1292-1300.
51. 孙黎, 邱红, 袁响林. 霜重鼓寒—2019ASCO后胃癌围手术期放疗再思考. 实用肿瘤杂志, 2019, 34(5): 396-401.
52. de Steur WO, van Amelsfoort RM, Hartgrink HH, et al. Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial. Ann Oncol, 2021, 32(3): 360-367.
53. Fitzgerald TL, Efird JT, Bellamy N, et al. Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5 058 patients. Cancer, 2017, 123(15): 2909-2917.
54. Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol, 2015, 16(9): 1090-1098.
55. Noordman BJ, Verdam MGE, Lagarde SM, et al. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial. Ann Oncol, 2018, 29(2): 445-451.
56. Cheng Y, Wang J, Li J. Comparative analysis of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy with resectable adenocarcinoma of esophagogastric junction in Siewert’s type Ⅱand Ⅲ. Int J Radiat Oncol Biol Phys (IJROBP), 2019, 105(1S): E182-E183.

Previous Article
Progress and prospect of reducing jaundice tretment in elderly patients with malignant obstructive jaundice

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Based on Siewert classification: controversy progress of the integration of type Ⅱ of adenocarcinoma of esophagogastric junction

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content